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Abstract
Background: Ligands for the Toll-like receptor (TLR) family can induce activation of cells of the innate immune
system and are widely studied for their potential to enhance adaptive immunity. Conjugation of TLR2-ligand
Pam3CSK4 to synthetic long peptides (SLPs) was shown to strongly enhance the induction of antitumor immunity.
To further improve cancer vaccination, we have previously shown that the novel TLR2-L Amplivant (AV), a modified
Pam3CSK4, potentiates the maturation effects on murine DCs. In the current study, we further assessed the
immunological properties of AV.
Methods: Naïve mice were vaccinated with a conjugate of either Pam3CSK4 or AV and an SLP to assess specific
T cell priming efficiency in vivo. The potency of AV and Pam3CSK4, either as free compounds or conjugated to
different SLPs, to mature murine DCs was compared by stimulating murine dendritic cells overnight followed by
ELISA and flow cytometry analysis. Murine tumor experiments were carried out by vaccinating mice carrying
established HPV16 E6 and E7-expressing tumors and subsequently analyzing myeloid and lymphoid cells infiltrating
the tumor microenvironment. Furthermore, tumor outgrowth after vaccination was monitored to enable comparison
of the efficiency to induce antitumor immunity by Pam3CSK-SLP and AV-SLP conjugates. To enhance therapeutic
efficacy, AV-SLP conjugate vaccination was combined with ablative therapies to assess whether synergism between
such therapies would occur.
Results: SLPs conjugated to AV induce stronger DC maturation, in vivo T cell priming and antitumor immunity
compared to conjugates with Pam3CSK4. Interestingly, AV-SLP conjugates modulate the macrophage populations in
the tumor microenvironment, correlating with a therapeutic effect in an aggressive murine tumor model. The potency
of AV-SLP conjugates in cancer vaccination operates optimally in combination with chemotherapy or photodynamic
therapy.
Conclusion: These data allow further optimization of vaccination-based immunotherapy of cancer by use of the
improved TLR2-ligand Amplivant.
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Background
Cells of the innate immune system can recognize
pathogen-associated molecular patterns (PAMPs). These
specific structures include virus-derived RNA or DNA,
bacterial cell wall-derived lipoproteins or sugar groups,
amongst others. The receptors of the innate immune sys-
tem recognizing these structures, pattern-recognition re-
ceptors (PRRs), are classified into major receptor families,
such as the Toll-like receptor (TLR) family. The latter
family consists of 10 receptors in human beings and 13 in
mice, which are either expressed on the cell surface or in
endosomes of many antigen-presenting cells (APCs) such
as dendritic cells (DCs) [1]. Triggering of TLRs by their
cognate ligand generally results in activation of APCs and
concomitant secretion of pro-inflammatory cytokines and
upregulation of co-stimulatory molecules on the cell sur-
face. These effects are essential in the induction of isotype
class switching of B cells and induction of efficient T cell
responses. Therefore, vaccinologists have extensively ex-
plored the use of several TLR-ligands as adjuvants in vac-
cines to prevent or treat infections and cancer [2–8].
The cell surface-expressed TLR2 can form a heterodi-
mer with either TLR1, TLR6 or in humans also with
TLR10. Binding of triacylated lipopeptides to TLR2/1
and binding of diacylated lipopeptides to TLR2/6 leads
to pro-inflammatory cytokine release [1], while TLR2/10
heterodimers are thought to act as inhibitory receptors
on human B cells and appear not to play a role in DCs
[9]. A synthetic triacylated lipopeptide, Pam3CSK4, con-
sisting of a central cysteine residue bound to three pal-
mitic acid chains and a 5 amino acid long peptide
(-SK4), was shown to be a highly efficient agonist of
TLR2 with a favorable solubility profile [10, 11].
In previous studies, we exploited the activating properties
of Pam3CSK4 by covalently conjugating the ligand to
synthetic long peptides (SLPs) and studied the potential of
such constructs as cancer vaccines [12–14]. Not only do
Pam3CSK4-SLP conjugates mature APCs, they also have
the potential to target conjugated antigens to TLR2-express-
ing APCs. This was exemplified by the strongly enhanced in
vivo T cell priming by Pam3CSK4-SLP conjugates compared
to a mixture of free Pam3CSK4 and SLP [14]. Interestingly,
while the maturation of DCs by Pam3CSK4 binding was
shown to be essential for efficient in vivo T cell priming,
TLR2 itself is not the mediator in the uptake of the
Pam3CSK4-SLP conjugates [12, 13]. Furthermore, we dem-
onstrated the superiority of Pam3CSK4-SLP conjugates in
the induction of antitumor immunity compared to a mix-
ture of free Pam3CSK4 and SLP [14].
Jin et al. co-crystallized the human TLR2/1 heterodi-
mer with Pam3CSK4 and thereby identified the residues
of the receptor interacting with Pam3CSK4 [15]. We hy-
pothesized that a hydrogen bond could be formed be-
tween the phenylalanine at position 312 of TLR1 and
the lipid tail of Pam3CSK4 when a nitrogen atom would
be introduced in one of the palmitic acid tails of
Pam3CSK4. Indeed, we found that this improved agonist
induced enhanced murine DC maturation [16]. We
named this novel TLR2-L Amplivant® (AV).
In the present study, we demonstrate the enhanced im-
munological potency of AV as an adjuvant in cancer im-
munotherapy. We found that AV conjugated to an SLP
induced stronger in vivo T cell priming than Pam3CSK4
conjugated to the same SLP. This may be explained by the
enhanced potency to mature APCs by AV, as AV conju-
gated to several distinct peptide sequences and free AV
are consistently superior to Pam3CSK4 in activation of
murine DCs. Moreover, anti-tumor vaccination was im-
proved by conjugating AV to an SLP harboring a tumor-
specific epitope. Combination treatments of SLP vaccin-
ation and either low-dose chemotherapy or photodynamic
therapy (PDT) have been described to work synergistically
[17, 18]. PDT is based on systemic injection of a photo-
sensitizer, followed by local tumor irradiation with a laser.
We show that a combination of these tumor ablative and
immunomodulatory therapies and Amplivant-SLP conju-
gate vaccines also acts synergistically in tumor eradication.
Methods
Cell lines
Tumor cell line TC-1 was provided as a kind gift by T.C.
Wu (Johns Hopkins University, USA). TC-1 was gener-
ated by retrovirally transducing lung fibroblasts derived
from C57BL/6 mice with the oncogenic E6 and E7 pro-
teins of HPV16 and c-H-ras oncogenes [19]. The TC-1
cells were maintained as previously described [20]. For
tumor experiments, cells with a low passage number (< 8)
were used. The D1 cell line is a growth factor-dependent
murine splenic DC cell line, showing highly similar char-
acteristics to natural occurring DCs [21]. D1 cells were
kindly provided by P. Ricciardi-Castagnoli (University of
Milano-Bicocca, Italy). The B3Z hybridoma cell line was
kindly provided by N. Shastri (University of California,
Berkeley, USA) and cultured as described previously [22].
All cell lines were tested by PCR for rodent viruses with
negative results. Mycoplasma tests routinely performed
for all cell lines by PCR were negative.
Peptides
The following synthetic long peptide sequences were ap-
plied in this study, either as free peptide or conjugated
to Pam3CSK4 or AV. SLPOVA CTL: DEVSGLEQLESIIN-
FEKLAAAAAK, SLPOVA Th: ISQAVHAAHAEINEAGR;
SLPHPV: GQAEPDRAHYNIVTFCCKCDS. Peptides were
synthesized and conjugated to AV as described previ-
ously [12].
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DC maturation
Bone-marrow derived DCs (BMDC) were isolated from
C57BL/6 mouse bone marrow and subsequently cul-
tured for 10 days as described elsewhere [21]. Either
BMDC or D1 cells were incubated overnight with the in-
dicated compounds in 96-wells culture plates. Super-
natant was taken from the well after incubation, and
where indicated cells were harvested and subjected to
flow cytometric analysis to determine the expression of
co-stimulatory markers.
Transgenic OT1 T cell activation
The CD8+ T cell compartment of OT1 mice fully consists
of T cells that are specific for the SIINFEKL CTL epitope
of ovalbumin. OT1 mice were sacrificed and spleen and
inguinal, brachial and axillary lymph nodes were harvested
to obtain OT1 T cells. A single cell suspension was made
of the harvested organs using 70 μm strainers (BD Biosci-
ences) and the suspension was subsequently enriched for
CD8+ T cells using a CD8+ T cell enrichment kit (BD). D1
cells pre-loaded for 24 h with the indicated constructs
were washed and then co-cultured with the enriched OT1
CD8+ T cells (15,000 DC: 50,000 T cells). After 24 h of
co-culture, 7.5 μg/ml brefeldin A (Sigma-Aldrich) was
added and the cells were left for 16 h at 37 °C/5% CO2.
Intracellular cytokine staining was performed to stain
IFNγ and TNFα in the OT1 CD8+ T cells, and subsequent
flow cytometry was used to determine the percentage of
cytokine-positive OT1 CD8+ T cells.
B3Z hybridoma activation by loading wildtype and
TAP−/− BMDC
The B3Z cell line is a hybridoma expressing CD8 and a
TCR specific for the SIINFEKL CTL epitope of OVA.
Because the sequence of nuclear factor associated with T
cell activation (NFAT) is linked to a lacZ reporter con-
struct, a chromogenic substrate conversion can be mea-
sured at 595 nm wavelength upon activation of the B3Z
cells. Therefore, this T cell hybridoma can be used to
measure the level of antigen presentation by APCs inde-
pendent of co-stimulatory signaling. We loaded 50,000
bone-marrow derived DCs from C57BL/6 mice and
TAP−/− C57BL/6 mice per well overnight with the indi-
cated constructs. The next day, the DCs were washed
and 50,000 B3Z T cells were added per well for a
co-culture at 37 °C. After 24 h, the supernatant was re-
moved and the substrate CPRG (Calbiochem) was added
to all wells. A short incubation at 37 °C revealed a color
change, measurable at 595 nm wavelength using a mi-
croplate absorbance reader (Bio-rad).
In vivo T cell priming
Naïve C57BL/6 mice (Charles River Laboratories) of 6–8
weeks old were vaccinated subcutaneously in the tailbase
with 5 nmole of the indicated ovalbumin-derived con-
structs dissolved in 50 μl PBS. This dose was selected
based on titration experiments conducted in earlier stud-
ies, in which we observed strong in vivo T cell induction
[14]. Fourteen days later, an identical boost vaccination
was given. Five days after the boost, all mice were sacri-
ficed and inguinal lymph nodes and spleen were har-
vested. A single cell suspension of the organs was made
using 70 μm strainers (BD Biosciences). The cells were
washed and stained with fluorescent antibodies directed
against CD3 and CD8 (eBioscience), tetramers specific for
the SIINFEKL CTL epitope, and 7-AAD to exclude dead
cells, either directly ex vivo (LN) or after a 7-day restimu-
lation by co-culture with irradiated OVA-expressing EG7
tumor cells (spleen). The stained cells were analyzed by
flow cytometry on a FACS Calibur (BD).
Vaccination of C57BL/6 mice with the constructs de-
rived from HPV16 E7 was performed by s.c. vaccination
(5 nmole per vaccine) on day 0, 14 and 23. Blood was col-
lected on day 29 and all mice were sacrificed on day 30 to
collect spleen and inguinal (draining) lymph node sam-
ples. Blood samples were analyzed for the presence of
Db-RAHYNIVTF tetramer-specific T cells by flow cytome-
try. A single cell suspension was generated of the spleens
and lymph nodes using 70 μm strainers to enable staining
with the Db-RAHYNIVTF tetramer and antibodies spe-
cific for CD3, CD8, CD62L, CD127 and KLRG1 [20]. The
stained cells were analyzed by flow cytometry on a FACS
Calibur (BD).
Tumor outgrowth
Naïve C57BL/6 mice (Harlan Laboratories) of 6–8 weeks
old were subcutaneously challenged with 100,000 TC-1
([19]) cells on day 0 in the right flank. On day 8, when
tumors were palpable in all mice, or day 10 when indi-
cated, a vaccination with the indicated constructs dis-
solved in 50 μl PBS was given s.c. in the tailbase. The
tumor sizes were measured at least twice a week by use
of a caliper. Mice were sacrificed when tumor sizes
reached 2000 mm3, in accordance with Dutch animal
welfare legislation.
Analysis of tumor-infiltrating lymphocytes and myeloid
cells upon vaccination
Naïve C57BL/6 mice (Harlan Laboratories) of 6–8 weeks
old were challenged with a TC-1 tumor as described
above. On day 10, mice were vaccinated with 5 nmole of
the indicated constructs dissolved in 50ul PBS by s.c.
tailbase vaccination. Tumor sizes were measured during
the course of the experiment by use of a caliper. On day
19, all mice were sacrificed. Approximately 50 ml of ster-
ile PBS was injected intracardially to flush the blood cir-
culation including the tumors. Tumors were accurately
dissected from the mice and left in complete medium on
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ice. The tumors were subsequently cut in small pieces
and mashed over 70 μm cell strainers (BD Biosciences)
to create a single cell suspension. Cells were washed and
stained using fluorescent antibodies (eBioscience) di-
rected against either lymphocyte or myeloid markers.
Fc-block using mouse serum was added to the procedure
to prevent aspecific antibody binding. Marker expression
on cells was analyzed using flow cytometry (LSRII, BD
Biosciences). Live myeloid cells were identified as
7-AAD−CD3−CD11b+. Within this gate, several subpop-
ulations were identified as described in the Results sec-
tion and Fig. 3, based on gating strategies applied by
others [23].
TLR2-L SLP conjugate and cisplatin combined treatment
in tumor-bearing mice
Naïve C57BL/6 mice (Harlan Laboratories) of 6–8 weeks
old were challenged with a TC-1 tumor as described
above. Five nmole of the indicated constructs was injected
subcutaneously in the tailbase in 50 μl PBS on day 10,
when the average tumor size was 12mm3. Cisplatin was
injected intraperitoneally in mice of indicated groups on
day 10 and 17, at a suboptimal dose of 4mg/kg as used
previously in our group [18]. The tumor sizes were mea-
sured 2 or 3 times a week by use of a caliper. Mice were
sacrificed when tumor sizes reached 2000mm3, in accord-
ance with Dutch animal welfare legislation.
Combined TLR2-L SLP conjugate vaccination and PDT
treatment in tumor-bearing mice
Naïve C57BL/6 mice (Harlan Laboratories) of 6–8 weeks
old were challenged with a TC-1 tumor as described
above. For these experiments, 5 nmole of the indicated
constructs was injected subcutaneously in the tailbase in
50 μl PBS on day 6 according to optimized protocols in
our lab. On day 6, tumors were palpable in all mice. On
day 8, photodynamic therapy (PDT) was performed on
mice in indicated groups by intravenous injection of 20
mg/kg Bremachlorin photosensitizer per mouse, followed
6 h later by local illumination of the tumor with a 662 nm
laser at 116mW/cm2 for 1000 s (total light dose 116 J/cm2),
as described elsewhere [17]. The tumor sizes were mea-
sured 2 or 3 times a week by use of a caliper. Mice were
sacrificed when tumor sizes reached 2000mm3, in accord-
ance with Dutch animal welfare legislation.
Results
The modified TLR2-L Amplivant improves conjugated SLP
vaccination
Modification of TLR2-L Pam3CSK4 resulted in the gener-
ation of Amplivant (AV), a TLR2-L with enhanced DC ac-
tivation potency [16]. In previous studies, we have shown
that generation of specific T cell responses by SLP is mark-
edly improved by conjugating the SLP to TLR2-L
Pam3CSK4 [12–14]. To test whether AV shares the ability
to efficiently induce specific T cell responses, we conju-
gated both AV and Pam3CSK4 to an ovalbumin-derived
SLP containing the CD8+ T cell epitope SIINFEKL
(SLPOVA CTL). DCs were loaded with titrating doses of ei-
ther Pam3CSK4 or AV conjugated to SLPOVA CTL or with
mixtures of free SLP and TLR2-L and subsequently
co-cultured with SIINFEKL-specific CD8+ T cells derived
from the transgenic OT1 mouse. At these low concentra-
tions, both Pam3CSK4- and AV-SLPOVA CTL conjugates
show a stronger induction of IFNγ and TNFα production
by OT1 T cells, as determined by intracellular cytokine
staining, than a mixture of free TLR2-L and SLPOVA CTL
(Fig. 1a, and b). Processing of the Pam3CSK4- and
AV-SLPOVA CTL conjugates occurred with similar effi-
ciency as no difference in OT1 T cell activation was ob-
served. In addition, we observe a total abrogation of MHC
class I-dependent activation of a T cell hybridoma (B3Z)
specific for the SIINFEKL CTL epitope (Additional file 1:
Figure S1) using cells lacking transporter associated with
antigen processing (TAP). This indicates that the process-
ing and presentation of the epitope follows a classical
cytosolic cross-presentation route after uptake.
Next, we vaccinated groups of naïve C57BL/6 mice sub-
cutaneously (s.c.) with either the Pam3CSK4- or
AV-SLPOVA CTL conjugate. All mice received a booster
vaccination 14 days later. Seven days after the boost, sig-
nificantly more Kb-SIINFEKL tetramer-positive CD8+ T
cells are detected in the vaccine-draining lymph nodes
upon vaccination with the AV-SLPOVA CTL conjugate,
compared to Pam3CSK4-conjugate vaccinated mice
(Fig. 1c). Also, significantly more specific CD8+ T
cells are detected in the AV-SLPOVA CTL-vaccinated
group after ex vivo restimulation of the splenocytes
(Fig. 1d). In line with our previous studies, conjugation of a
TLR2-L to an SLP improves the induction of specific CD8+
T cells as compared to a mixture of free SLP and TLR2-L
[14]. As HPV16 is a clinically more relevant tumor antigen,
we also conjugated AV and Pam3CSK4 to an SLP derived
from HPV16 E7 which harbors a Db-restricted MHC class I
epitope [24]. After receiving three s.c. vaccinations, an en-
hanced average percentage of E7-specific CD8+ T cells is
detected in blood and spleen in the mice vaccinated with
AV-SLPHPV, albeit not significantly (Additional file 1: Figure
S2A, and B). Notably, the mice in the AV-SLPHPV conjugate
group with the highest percentage of HPV16 E7-specific
CD8+ T cells also had a higher percentage of antigen-spe-
cific effector/effector memory T cells, as indicated by the
low expression of CD127 or CD62L and high expression of
KLRG1 (Additional file 1: Figure S2C, and D).
Amplivant induces potent murine DC activation
In our previous study, we reported that AV induces en-
hanced murine DC maturation compared to Pam3CSK4
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[16]. Looking more in-depth at the maturation potential
of non-conjugated AV reveals enhanced IL-12p40 pro-
duction and upregulation of MHC class II molecules
(I-Ab) and co-stimulatory markers CD40 and CD86 by
both a murine DC cell line and bone marrow-derived
DCs (BMDC; Additional file 1: Figure S32) in compari-
son with non-conjugated Pam3CSK4. To determine
whether AV also induces enhanced DC maturation upon
conjugation to a an SLP which improved T cell priming,
we stimulated murine BMDCs with titrating concentra-
tions of either Pam3CSK4 or AV conjugated to three dif-
ferent SLPs: ovalbumin-derived SLPOVA CTL and SLPOVA
TH and HPV16 E7-derived SLPHPV [14, 25]. Indeed,
IL-12p40 production by BMDC upon stimulation with
AV-conjugated SLP was significantly higher than
Pam3CSK4-conjugated SLP (Fig. 2a, b and c). Although
not always as pronounced as the IL-12p40 production,
also the co-stimulatory marker CD86 was upregulated
more strongly in response to stimulation with the
AV-SLP conjugate (Fig. 2d, e and f) [24]. A representa-
tive dilution range is shown separately for each conju-
gated SLP as conjugation of AV to an SLP leads to
different physicochemical properties for each SLP. Be-
sides, the conditions of each cellular assay are slightly
different. These data show that AV retains its effective
DC activating capacity upon conjugation to SLPs, irre-
spective of SLP sequences.
Favorable modulation of tumor-associated myeloid
compartment upon vaccination of tumor-bearing mice
with AV-SLP conjugate
Next, we examined the effects of AV-SLP conjugate vac-
cination in mice carrying an established tumor. First,
naïve C57BL/6 mice were challenged with TC-1 tumor
A
C D
B
Fig. 1 AV-SLP conjugate vaccination induces in vitro T cell activation and enhances in vivo priming of endogenous T cells. Percentages of IFNγ-
(a) and TNFα- (b) producing transgenic OT1 T cells after 48 h of co-culture with D1 DCs that were loaded overnight with the indicated SLPOVA CTL
peptide mixed with Pam3CSK4 or AV, or conjugated to Pam3CSK4 or AV. Percentages of Kb-SIINFEKL+ CD8β+ T cells in (c) vaccine-draining lymph
node ex vivo and (d) restimulated splenocytes of C57BL/6 mice vaccinated with mixtures of Pam3CSK4 and SLPOVA CTL (Pam + SLPOVA mix), AV
and SLPOVA (AV + SLPOVA mix), Pam-SLPOVA conjugate or AV-SLPOVA conjugate. Five nmole of each SLP, free adjuvant or TLR2-L SLP conjugate
were administered, i.e. a mixture of TLR2-L and SLP contained 5 nmole of TLR2-L and 5 nmole SLP. Significance determined by unpaired t-test in
(c) and (d): * p < 0.05, ** p < 0.01. All presented experiments were repeated at least twice with similar outcome
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cells which express the HPV16 oncoproteins E6 and E7
[19]. After 10 days, when average tumor sizes reached
12mm3, mice were s.c. vaccinated with either
AV-SLPHPV or vehicle only. Nine days after the vaccin-
ation, when the expected peak of the T cell response and
tipping point in the tumor regression phase coincide, all
mice were sacrificed and the phenotypes of the infiltrat-
ing lymphocyte and myeloid populations were analyzed.
No significant differences were seen in tumor size at this
time point (data not shown). Vaccination with the conju-
gates led to a strong infiltration of CD8+ T cells into the
tumor while the percentages of CD4+ T cells in the
tumor were similar to those in untreated mice (Fig. 3a).
Of these CD8+ T cells, an average of approximately 10 %
was specific for the CTL epitope (RAHYNIVTF) embed-
ded in the conjugated vaccine SLP. In a recent study,
four tumor-infiltrating myeloid populations were identi-
fied based on the expression of CD11b, F4/80 and Ly6C
(Additional file 1: Figure S4.A) [23]. Of these, the fre-
quency of inflammatory macrophages (CD3−CD11b+Ly6-
ChiF4/80hi) after peptide vaccination correlated with the
infiltration of CD8+ T cells. In the present study, we
observe a highly significant increase in the frequency of
intratumoral inflammatory macrophages upon vaccination
with AV-SLPHPV. At the same time, vaccination also led to
decreased levels of tissue-resident macrophages
(CD3−CD11b+Ly6CINTF4/80INT; Fig. 3b). In addition, the
AV-SLPHPV conjugate induces stronger upregulation of
the DC marker CD11c on all gated myeloid populations
except for the granulocytic myeloid cells, which may re-
flect differentiation towards a more DC-like phenotype. A
direct comparison between AV-SLPHPV and Pam-SLPHPV
conjugate vaccination revealed that both conjugates are
highly similar in their potency to induce tumor infiltration
by T cells and modulation of the intratumoral myeloid
populations (Additional file 1: Figure S4.B, C and D).
Overall, these results provide important insights into the
effects of TLR2-L SLP conjugate vaccination in TC-1
tumor-bearing mice, showing the favorable skewing effect
towards the inflammatory macrophage phenotype by
AV-SLPHPV conjugate vaccination.
AV-SLP conjugate vaccination improves therapeutic antitumor
response
In previous studies, we found that conjugates of
Pam3CSK4 and SLP were superior to mixtures of
Pam3CSK4 and SLP in prophylactic tumor models. In the
present study, we s.c. vaccinated mice carrying an estab-
lished TC-1 tumor with AV-SLPHPV or a mixture of AV
and SLPHPV and found that conjugation of AV to SLPHPV
significantly enhanced the survival of TC-1-bearing mice
in a therapeutic setting (vaccination on day 8 after tumor
challenge; Fig. 4a). To study whether the favorable effects
in the tumor microenvironment induced by AV-SLPHPV
conjugate vaccination led to efficient tumor eradication,
C57BL/6 mice carrying a palpable TC-1 tumor were
A CB
FED
Fig. 2 AV retains its superior capacity in induction of DC maturation over Pam3CSK4 upon conjugation. (A – C) Concentration of IL-12p40 in the
supernatant of BMDCs stimulated overnight with ovalbumin-derived SLPOVA CTL or SLPOVA Th or HPV16 E7-derived SLPHPV, conjugated to either
Pam3CSK4 or AV. (D-F) Expression of CD86 (MFI; mean fluorescence intensity) on BMDCs stimulated overnight as in Fig. 2a, B and c. Results are
representative of at least three independently performed experiments with each of the conjugated SLPs. Significance determined by unpaired
t-test: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
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vaccinated with either AV-SLPHPV or Pam-SLPHPV. Tu-
mors of mice vaccinated with AV-SLPHPV on day 8 after
tumor challenge remained significantly smaller during the
initial tumor growth phase than those of mice vaccinated
with Pam-SLPHPV (Additional file 1: Figure S5A) which
was also reflected in improved early phase survival be-
tween day 20 and 40 (Additional file 1: Figure S5B). A
stronger and more significant reduction in tumor size was
observed when mice were vaccinated with AV-SLPHPV
conjugate on day 10 after tumor challenge, when mice
have developed larger tumor sizes (approximately 12
mm3) at the moment of vaccination (Fig. 4b). Interest-
ingly, the time point at which tumors start to regress in
the AV-SLP conjugate-vaccinated group is earlier than in
the Pam-SLP conjugate-vaccinated group. Moreover,
AV-SLPHPV conjugate vaccination resulted in a significant
survival benefit compared with Pam-SLPHPV-vaccinated
mice (Fig. 4c).
Combinations of ablative therapy and AV-SLP vaccination
synergize in tumor eradication
The observation that only approximately 10–20% of
TC-1 tumor-bearing mice are cured by therapeutic vac-
cination (Fig. 4a, c) shows that AV-SLP conjugate vac-
cination on its own is not capable to mediate tumor
eradication in the majority of animals in this model. In a
A
B 421 3
C
Fig. 3 Modulation of intratumoral lymphoid and myeloid compartment by AV-SLPHPV conjugate. Mice were vaccinated ten days after s.c. TC-1
tumor challenge and sacrificed on day 9 after vaccination to analyze tumor-infiltrated lymphocytes and myeloid populations. (a) Percentages of CD4+
T cells, CD8+ T cells (of live cells; 7-AAD−) and Db-RAHYNIVTF+ (HPV16 E7-specific) CD8+ T cells in tumor tissue as determined by flow cytometry. One
outlier removed from group Pam-SLPHPV in plot of tetramer (TM)
+ CD8+ T cells after performance of Grubb’s test. (b) Percentages of described myeloid
subpopulations within CD3−CD11b+ gated live cells from tumor tissue. (c) Expression of CD11c on described myeloid subpopulations. Significance
determined by unpaired t-test: ** p < 0.01
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clinical setting, patients usually receive standard-of-care
chemotherapy and/or radiotherapy to treat HPV16-in-
duced cancer. SLP vaccination has recently been shown to
synergize with a suboptimal dose of cisplatin in the eradi-
cation of TC-1 tumors in mice, partially explained by the
enhanced apoptosis of tumor cells by TNFα from
SLP-induced T cells in the presence of cisplatin [18].
Therefore, we tested whether synergistic tumor eradica-
tion could also be achieved upon combined cisplatin and
AV-SLPHPV treatment in TC-1-bearing mice. Mice were
vaccinated s.c. with AV-SLPHPV on day 10 after tumor
challenge, while cisplatin was injected intraperitoneally at
a dose of 4mg/kg cisplatin, well below the maximum tol-
erated dose. The treatment timeline is depicted in Fig. 5a.
Both cisplatin treatment and AV-SLPHPV vaccination
alone delayed the outgrowth of most tumors but were not
curative for the majority of mice (Fig. 5b). The combin-
ation treatment resulted in a significantly better survival
(71% versus 12.5%) compared to the group vaccinated
with AV-SLPHPV only.
Another immunomodulatory therapy, photodynamic
therapy (PDT), acts by laser-induced local cytotoxicity
after administration of the photosensitizer Bremachlorin
which accumulates selectively in tumor tissue [17]. We
combined PDT with s.c. AV-SLPHPV vaccination to exam-
ine whether these treatments act synergistically. PDT
treatment or AV-SLPHPV vaccination on itself delayed
tumor outgrowth in the TC-1 model (1 mouse out of 8
cured in both groups; 12.5%; Fig. 5c), while the combin-
ation of PDT with AV-SLPHPV induced eradication of tu-
mors in 8 out of 9 mice (89%; Fig. 5c). Out of the 8 cured
mice, 7 developed a strong memory response as these
mice were protected from a rechallenge with TC-1 tumor
cells in the opposite flank. Both surviving mice of the
AV-SLPHPV and PDT monotherapy groups were protected
as well from the rechallenge (Fig. 5c). These data show
that AV-SLP conjugate vaccines can be effectively com-
bined with chemotherapy or photodynamic therapy.
Discussion
We consistently observe enhanced maturation of murine
DCs by AV either as a free ligand or conjugated to any
peptide sequence tested so far. Interestingly, the physical
and chemical properties of each conjugate may differ, as
observed before [26]. While the Pam- and AV-SLPOVA
CTL conjugates still retain strong activation potency in
A
B C
Fig. 4 TC-1 tumors initially grow slower in mice vaccinated with AV-SLPHPV conjugate. (a) Kaplan-Meier survival plot of C57BL/6 mice carrying a
TC-1 tumor vaccinated with indicated vaccines. Data pooled from two identically performed experiments, total number of mice per group
indicated as n. Significant difference between AV + SLPHPV mix and AV-SLPHPV (* p = 0.014) determined by Gehan-Breslow Wilcoxon test. (b)
Average tumor size per group of mice vaccinated with either AV-SLPHPV or Pam-SLPHPV conjugates, or not vaccinated (Untreated). Average tumor
size followed in time until first mouse was sacrificed due to tumor burden. Significance determined by Mann Whitney t-test (* p < 0.05; ** p < 0.01).
(c) Kaplan-Meier plot showing survival of mice vaccinated in same experiment as (b). Significance determined by log-rank test (** p < 0.01)
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AB
C
Fig. 5 (See legend on next page.)
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terms of IL-12p40 induction in the picomolar range, the
Pam-SLPOVA Th- and Pam-SLPHPV-conjugates lose their
activity in the low nanomolar range. As the peptide part
of each conjugate greatly differs in amino acid compos-
ition, also the solubility and binding stability may vary
depending on the amount of hydrophilic and hydropho-
bic residues.
After binding of Pam3CSK4 and AV to TLR2 on the cell
surface of DCs and the subsequent maturation process,
the constructs are ingested and processed by the DCs
resulting in the generation of the exact MHC ligands [12].
Using transgenic OT1 cells as a T cell read-out, we found
that both Pam- and AV-conjugated SLPs are efficiently
taken up and processed but do not differ in their capacity
to induce T cell activation. This may be explained by the
fact that the DC activation and concomitant cytokine ex-
pression and upregulation of co-stimulatory markers
reach a saturating level for activation of the low-threshold
OT1 transgenic T cells. Both conjugates outperformed a
mixture of SLP and either AV or Pam3CSK4. We have re-
ported the superiority of conjugates over mixtures of
TLR2-L and SLP before [12], which can be explained by
an enhanced uptake of the TLR2-L SLPOVA CTL conjugates
through DC targeting by their lipophilic properties.
In contrast to these in vitro data, a significant difference
was found in potency of the two conjugated ligands with
respect to T cell priming in vivo, as the AV-SLPOVA conju-
gates were shown to more effectively expand T cells of the
murine endogenous T cell repertoire. Comparing
AV-SLPHPV and Pam-SLPHPV conjugate–induced specific
T cells, differences in T cell activation markers were less
pronounced. However, differential potency in T cell activa-
tion by AV and Pam3CSK4 was suggested by skewing of
the T cell response towards a more effector (memory) T
cell-like phenotype which was observed in part of the
mice vaccinated with the AV-SLPHPV conjugate. Based on
their general molecular structure Pam3CSK4 and AV
share similar in vivo targeting potential. Therefore, the en-
hanced priming of CD8+ T cells is most likely explained
by the stronger binding of AV to TLR2-expressing APCs.
In a previous study, we have assessed the influence of DC
maturation on T cell priming by conjugating either the
functional R-Pam3CSK4 or dysfunctional S-Pam3CSK4
stereoisomer to an SLP [13]. Although S-Pam-SLP
conjugates could induce T cell priming in vivo, the
R-Pam-SLP performed significantly better. Therefore, it is
likely that the enhanced activation of DCs by AV posi-
tively affects the strength of T cell responses.
Given the results discussed above, we analyzed whether
AV-SLP conjugates were also more effective as therapeutic
vaccines in an established HPV-tumor model. As the data
in Fig. 4b and c demonstrate, AV-SLPHPV vaccination has
superior antitumor efficacy over Pam-SLPHPV vaccination.
In this setting, mice had large established tumors, indicat-
ing the strength of AV-SLPHPV-induced antitumor im-
mune responses. Mice carrying a tumor that was just
palpable (day 8 after tumor challenge) also benefited
stronger from AV-SLPHPV than Pam-SLPHPV vaccination,
although differences were smaller (Additional file 1: Figure
S5) suggesting that antigenic load may affect therapeutic
vaccination potency. These data show that the enhanced
TLR potency of AV is also beneficial for therapeutic anti-
tumor efficacy.
The mechanism behind the decreased tumor growth in
AV-SLPHPV-vaccinated mice was studied further by phe-
notyping the tumor-infiltrating lymphocytes and myeloid
cells. The myeloid infiltrate can be highly heterogeneous
within tumors but much can be learned from studies fo-
cusing on the roles of specific myeloid subtypes in
immunization and infection settings [27]. Ly6Chi mono-
cytes are described to be precursors of tumor-associated
macrophages and inflammatory DCs. The latter are cap-
able of efficient antigen presentation and retain Ly6Chi ex-
pression after differentiation. The Ly6Chi DCs play an
important role in the onset of TH1 T cell responses and
may therefore be considered reminiscent of M1 myeloid
cells [28]. The inflammatory macrophages detected in this
study also expressed intermediate levels of CD11c
(Fig. 3d), the expression of which was strongly upregulated
by AV-SLPHPV, but it remains to be determined whether
these cells share the same fate and properties with the in-
flammatory DCs.
The expression of TLR2 is very low or absent on T cells
but abundant on several myeloid cells [29], which suggests
that AV-SLPHPV may have a direct effect on myeloid pop-
ulations in the tumor area besides the induction of specific
T cells via APCs in lymphoid organs. Unfortunately, not
much is known about TLR2 expression on these cell
(See figure on previous page.)
Fig. 5 Combination of AV-SLPHPV conjugate vaccination and immunomodulatory therapy in TC-1 tumor model. (A) Overview of experimental
setup (timelines). Numbers indicate number of days after tumor challenge. (B) Tumor growth curves and Kaplan-Meier survival plot of combination
treatment of AV-SLPHPV conjugate vaccination and i.p. cisplatin treatment. Numbers in graph indicate number of cured mice of total in group. Results
are shown of one of two experiments with similar outcome. (C) Combination treatment of AV-SLPHPV conjugate vaccination and photodynamic therapy
(PDT). Tumor growth curves and Kaplan-Meier survival plots of groups of mice carrying a TC-1 tumor vaccinated with indicated vaccines. Bottom Kaplan-
Meier plot represents survival of mice after re-challenge with TC-1 tumor cells at day 55. Significance determined by log-rank test; * p< 0.05; ** p< 0.01;
*** p< 0.001
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populations. Both AV- and Pam-SLPHPV conjugates re-
duced the frequency of tissue-resident macrophages. Al-
though likely, we cannot conclude whether tissue-resident
macrophages have been modulated towards an inflamma-
tory macrophage phenotype. Another theoretical explan-
ation for the observed skewing may be found in the
induction of tumor cell death. Ma et al report on the at-
traction of myeloid cells into the tumor by ATP released
from dying cancer cells [30]. These cells could further dif-
ferentiate towards CD11b+CD11c+Ly6Chi cells, similar to
the inflammatory macrophage population we find in tu-
mors in the current study. Therefore, by directly inducing
tumor cell death, AV may indirectly attract and cause dif-
ferentiation of myeloid populations in the tumor micro-
environment. Another attractive explanation is that the
tumor microenvironment is influenced by the induced T
cell response. As we have shown that AV conjugated to
HPV16 E6-derived SLPs can stimulate Th1-type T cells in
tumor draining LN cells derived from cervical cancer pa-
tients [26], it is conceivable that this type of T cells can in-
directly skew the tumor environment to a more favorable
myeloid cell composition [23].
Figure 4 shows that AV-SLPHPV vaccination alone does
not suffice to permanently eradicate most TC-1 tumors.
However, we saw highly potent effects of AV-SLP vaccin-
ation in combination treatment with cisplatin and photo-
dynamic therapy (PDT), mediating cures in the large
majority of mice where either treatment alone was only ef-
fective in a small minority of animals (Fig. 5b, c). This syn-
ergistic effect may be explained by several simultaneously
operating mechanisms: 1) induction of immunogenic cell
death by cisplatin, leading to release of several immuno-
modulators from dying tumor cells [31]; 2) secretion of
TNFα by the SLP vaccine-induced T cells in the tumor
microenvironment and increased sensitivity of tumor cells
to TNFα-mediated apoptosis in the presence of cisplatin
[18], 3) selective depletion of immunosuppressive imma-
ture myeloid cells by chemotherapy as was shown for car-
boplatin and paclitaxel [32]. As the AV-SLPHPV conjugate
even more adequately induces T cell responses than SLPs
alone, it is likely that the same mechanisms apply here.
Our group recently reported on the synergistic effects of
a combination of PDT and immunotherapy [17]. Also, the
combination of PDT with AV-SLPHPV vaccination resulted
in strongly improved established tumor eradication. The
mechanisms underlying the synergism observed by com-
bination of PDT and AV-SLPHPV conjugate vaccination
are likely explained by induction of immunogenic cell
death [17]. Elevated cross-presentation and T cell activa-
tion in combination with our optimized conjugate vaccine
resulted in effective synergy in immune control of tumors
and cure of almost all animals.
Overall, we conclude that the modification of
Pam3CSK4 as applied in the TLR2-L Amplivant™ results
in enhanced immunological effects which are beneficial in
cancer immunotherapy in mice, particularly when used in
synthetic long peptide-conjugate vaccines. These promis-
ing results pave the way for further clinical testing of
AV-SLP conjugates. Currently, a phase I/II clinical trial
has started to assess the dosing and safety profile of two
HPV16 E6-derived SLPs conjugated to AV.
Conclusions
The present study provides insight in the enhanced im-
munological effects of the novel TLR2-L Amplivant™ (AV)
in comparison with the reference compound Pam3CSK4.
We show that the enhanced activation of DCs in vitro also
translates to enhanced endogenous T cell priming in vivo
when AV is conjugated to SLP. For the first time, we show
that AV-SLP conjugates applied in an established tumor
setting induced therapeutic antitumor efficacy, which was
stronger than Pam-SLPHPV conjugate vaccination. The
synergy between SLP-conjugated AV and each of two dif-
ferent standard anti-cancer therapies shows the strong
therapeutic potential of this TLR2-L.
Additional file
Additional file 1: Figure S1. Activation of B3Z hybridoma after
co-culture with D1 DCs loaded with 1uM of indicated compounds.
Activation determined by spectrophotometry (OD 595 nm). WT BMDC:
BMDCs derived from wildtype C57BL/6; TAPKO BMDC: BMDCs derived
from TAP-deficient C57BL/6 mice; SIINFEKL: sequence of short ovalbumin-
derived CTL epitope. Similar results were obtained in one additional
experiment. Significance determined by unpaired t-test: **** p < 0.0001.
Figure S2. Vaccine-induced HPV16 E7-specific T cell activation. C57BL/6
mice were vaccinated three times s.c. with 5 nmole of either AV-SLPHPV or
Pam-SLPHPV conjugate (day 0, 14 and 23). Percentage of D
b-RAHYNIVTF-
tetramer+ CD8+ T cells detected ex vivo in blood on day 29 (A) and in
spleen on day 30 (B). Percentages of effector/effector memory T cells
detected ex vivo in spleen (day 30) within tetramer+ CD8+ T cell population,
characterized as CD62L− KLRG1+ TM+ CD8+ T cells (C) and CD127− KLRG1+
TM+ CD8+ T cells (D). Figure S3. Maturation of murine DCs as determined
by secretion of IL-12p40 and expression of activation markers. (A)
Concentration of IL-12p40 detected in the supernatant of 24 h stimulated
D1 DCs. Expression of CD86 and MHC class II (B) and CD40 (C) on D1 DCs
after stimulation for 24 h with non-conjugated Pam3CSK4 or non-conjugated
AV. (D) Concentration of IL-12p40 detected in the supernatant of 24 h
stimulated BMDCs and (E) expression of CD40 on BMDCs. Graphs are
representative of at least 3 comparable experiments. Significance in
Figure S2. A and D determined by unpaired t-test: * p < 0.05, ** p < 0.01,
*** p < 0.001, **** p < 0.0001; Significance in Figure S2.E: Wilcoxon
matched-pairs signed-rank test * p = 0.016. Figure S4. AV-SLPHPV and
Pam-SLPHPV have similar potency in induction of T cell tumor infiltration and
myeloid cell modulation. (A) Gating strategy for identification of
inflammatory macrophages (1), tissue-resident macrophages (2), DC-like
macrophages (3) and granulocytic myeloid cells (4). (B) Percentages of CD8+
T cells (of live cells; 7-AAD−) and Kb-SIINFEKL+ CD8+ T cells in tumor tissue as
determined by flow cytometry. (C) Percentages of described myeloid
subpopulations within CD3−CD11b+ gated live cells from tumor tissue,
depicted as ratio calculated by division by the percentage measured in
Untreated animals. (D) Expression of CD11c on described myeloid
subpopulations, depicted as ratio calculated by division by the MFI
measured in Untreated animals. Data from B-D pooled from two independently
and identically performed experiments. Significance determined by unpaired
t-test: ** p < 0.01, **** p < 0.0001. Figure S5. Therapeutic vaccination by
AV-SLPHPV or Pam-SLPHPV conjugate on day 8 after TC-1 tumor challenge.
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Data pooled from 5 identically performed experiments; 47 mice per group.
(A) Tumor volumes (mm3) measured in TC-1 tumor-carrying C57BL/6 mice
after vaccination with AV-SLPHPV or Pam-SLPHPV conjugate. X-axis indicates
days after vaccination; days of measurements in the different experiments
were distributed over 2-day intervals to enable combining of data.
Non-parametric Wilcoxon test revealed significant difference (* p = 0.016)
between vaccinated groups. (B) Kaplan-Meier survival plot of C57BL/6 mice
carrying a TC-1 tumor vaccinated with AV-SLPHPV or Pam-SLPHPV conjugate.
(PDF 189 kb)
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